From: A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
Arm A
Arm B
Dose level
Gemcitabine
Nab-paclitaxel
0
1000Â mg/m2
800Â mg/m2
100Â mg/m2
-1
600Â mg/m2
75Â mg/m2
-2
-